Skip to main content
. 2022 Mar 5;23(5):2864. doi: 10.3390/ijms23052864

Figure 2.

Figure 2

Impact of rapeseed nanoliposomes encapsulating or not encapsulating TGF-β1 on chondrocyte viability. Cells were untreated or exposed to 100 µg/mL of nanoliposomes encapsulating or not 0.1, 1, 10 or 100 ng/mL of recombinant TGF-β1 for 24 h or 7 days. (A) Metabolic activity measured using MTT assay at day 7. The control condition was used as the reference value corresponding to an activity of 100%. (B) Cell proliferation estimated by measuring DNA concentrations at day 7. (C) In vitro cytotoxicity measured by LDH assay at day 1. The reported data are represented as mean ± SD of at least four individual experiments. Significance compared to Ctrl is indicated as * with p < 0.01. Ctrl—control cells meaning untreated chondrocytes; LDH—lactate dehydrogenase; MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NL—empty nanoliposomes; NL-TGF—TGF-β1-loaded nanoliposomes; NL-TGF 0.1—nanoliposomes encapsulating 0.1 ng/mL of TGF-β1; SD—standard deviation; TGF-β1—transforming growth factor-β1.